<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT03043482</url>
  </required_header>
  <id_info>
    <org_study_id>VS 105 SAD MAD 001</org_study_id>
    <nct_id>NCT03043482</nct_id>
  </id_info>
  <brief_title>A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of VS 105</brief_title>
  <official_title>A Phase 1, Single and Multiple Ascending Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of VS 105 Following Oral Administration in Healthy and Hemodialysis Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vidasym, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vidasym, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate the safety, tolerability, and PK following single and&#xD;
      multiple ascending dose administration of VS-105 in healthy subjects and patients with&#xD;
      chronic kidney disease stage 5D (CKD-5D) on hemodialysis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a first in human, 3 part, single and multiple ascending dose study in healthy&#xD;
      subjects and subjects with end stage renal disease (ESRD) requiring hemodialysis (HD). A&#xD;
      Safety Monitoring Committee (SMC) will evaluate safety data from each dose cohort before&#xD;
      proceeding with the subsequent cohort. The SMC will also review data from each Part of the&#xD;
      study before proceeding to the next scheduled Part.&#xD;
&#xD;
      In Part 1, single ascending doses (SAD) of VS 105 will be administered to approximately 5&#xD;
      dose cohorts of 8 healthy subjects each. In Part 2, multiple ascending doses (MAD) of VS 105&#xD;
      will be administered to approximately 3 dose cohorts of 8 healthy subjects each. VS 105 doses&#xD;
      for MAD cohorts in Part 2 will be determined by the SMC and based on results from Part 1.&#xD;
&#xD;
      In Part 3, MAD of VS 105 will be administered to approximately 3 successive dose cohorts that&#xD;
      will each include 4 subjects with ESRD requiring HD. VS 105 doses used in Part 3 will be&#xD;
      selected by the SMC based on review of safety and/or pharmacokinetic (PK) results from Part 1&#xD;
      and Part 2.&#xD;
&#xD;
      Parts 1 &amp; 2 of the study will assess the safety, tolerability, and PK of ascending doses of&#xD;
      VS 105 to determine the dose range that is safe and well tolerated in healthy subjects.&#xD;
&#xD;
      Part 3 of the study will assess the safety, tolerability, and PK of various doses of VS 105&#xD;
      in subjects with ESRD requiring HD (ie, HD subjects), who represent the target population&#xD;
      with secondary hyperparathyroidism (SHPT).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 24, 2017</start_date>
  <completion_date type="Actual">March 31, 2018</completion_date>
  <primary_completion_date type="Actual">March 31, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability of single and multiple ascending doses of VS 105 administered orally to healthy and HD subjects (numbers and percentages of adverse events).</measure>
    <time_frame>3 weeks</time_frame>
    <description>Adverse events will be counted within each treatment and study part. The numbers and percentages of adverse events will be tabulated by body system, preferred term, and severity.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic (PK) of VS-105 in serum: area under the serum concentration-time curve from time zero to the time of the last quantifiable concentration</measure>
    <time_frame>pre-dose and 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12 and 16 hours and 2, 3, 7, 8, 9, 14, 15, 16 days after dosing.</time_frame>
    <description>AUC0-last: The area under the serum concentration-time curve from time zero to the time of the last quantifiable concentration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK of VS-105 in serum: area under the serum concentration-time curve from time zero to infinity.</measure>
    <time_frame>pre-dose and 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12 and 16 hours and 2, 3, 7, 8, 9, 14, 15, 16 days after dosing.</time_frame>
    <description>AUC0-∞: The area under the serum concentration-time curve from time zero to infinity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK of VS-105 in serum: observed maximum serum concentration following drug administration</measure>
    <time_frame>pre-dose and 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12 and 16 hours and 2, 3, 7, 8, 9, 14, 15, 16 days after dosing.</time_frame>
    <description>Cmax: The observed maximum serum concentration following drug administration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK of VS-105 in serum: terminal elimination half-life</measure>
    <time_frame>pre-dose and 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12 and 16 hours and 2, 3, 7, 8, 9, 14, 15, 16 days after dosing.</time_frame>
    <description>T1/2: The terminal elimination half-life</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK of VS-105 in serum: time to reach the maximum concentration after drug administration</measure>
    <time_frame>pre-dose and 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12 and 16 hours and 2, 3, 7, 8, 9, 14, 15, 16 days after dosing.</time_frame>
    <description>Tmax: The time to reach the maximum concentration after drug administration</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Serum calcium (ionized) in healthy and HD subjects</measure>
    <time_frame>Pre-dose and 1, 2, 15, 21 days after dosing</time_frame>
    <description>To evaluate the changes from baseline in concentrations of serum calcium (ionized) in healthy and HD subjects after multiple doses of VS 105 (Part 2 and Part 3 only).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum phosphorous in healthy and HD subjects</measure>
    <time_frame>Pre-dose and 1, 2, 15, 21 days after dosing</time_frame>
    <description>To evaluate the changes from baseline in concentrations of serum phosphorous in healthy and HD subjects after multiple doses of VS 105 (Part 2 and Part 3 only).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum intact parathyroid hormone (iPTH) in healthy and HD subjects</measure>
    <time_frame>Pre-dose and 1, 2, 15, 21 days after dosing</time_frame>
    <description>To evaluate the changes from baseline in concentrations of serum intact parathyroid hormone (iPTH) in healthy and HD subjects after multiple doses of VS 105 (Part 2 and Part 3 only).</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">69</enrollment>
  <condition>Chronic-kidney Disease Stage 5D on Stable Hemodialysis</condition>
  <arm_group>
    <arm_group_label>Single VS-105/placebo to healthy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single ascending dose VS-105 or placebo to healthy subjects</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Multiple VS-105/placebo to healthy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple ascending dose VS-105 or placebo to healthy subjects</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Multiple VS-105/placebo to HD subjects</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple ascending dose VS-105 or placebo to hemodialysis (HD) subjects</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Single VS-105/placebo to healthy</intervention_name>
    <description>In Part 1, single ascending doses of VS-105 or placebo will be administered to approximately 5 cohorts of 8 healthy subjects in each cohort with 6 receiving active and 2 receiving placebo.</description>
    <arm_group_label>Single VS-105/placebo to healthy</arm_group_label>
    <other_name>CK15</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Multiple VS-105/placebo to healthy</intervention_name>
    <description>In Part 2, multiple ascending doses of VS 105 or placebo will be administered each morning over 7 consecutive days to approximately 3 cohorts of 8 healthy subjects in each cohort with 6 receiving active and 2 receiving placebo..</description>
    <arm_group_label>Multiple VS-105/placebo to healthy</arm_group_label>
    <other_name>CK15</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Multiple VS-105/placebo to HD subjects</intervention_name>
    <description>In Part 3, multiple ascending doses of VS 105 will be administered over 14 consecutive days to approximately 3 cohorts that will each include 4 hemodialysis subjects with 3 receiving active drug and 1 receiving placebo.</description>
    <arm_group_label>Multiple VS-105/placebo to HD subjects</arm_group_label>
    <other_name>CK15</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Healthy Subjects (Parts 1 &amp; 2)&#xD;
&#xD;
        Eligible healthy subjects must meet all of the following criteria to quality for enrollment&#xD;
        in this study:&#xD;
&#xD;
          1. Healthy male and female subjects between 18 and 60 years of age (inclusive). Healthy&#xD;
             status, as determined by the investigator, will be based on medical and surgical&#xD;
             history, as well as a complete physical examination including vital signs,&#xD;
             electrocardiogram (ECG), and laboratory test results.&#xD;
&#xD;
          2. A body mass index (BMI) between 18 and 35 kg/m2 (inclusive).&#xD;
&#xD;
          3. Female subjects of childbearing potential must be non pregnant and non lactating, and&#xD;
             have a negative serum pregnancy test at Screening and a negative serum or urine&#xD;
             pregnancy test on Day 1 (if initial serum human chorionic gonadotropin [hCG] test&#xD;
             results are indeterminate, follow up testing should be performed). Female subjects of&#xD;
             childbearing potential (including perimenopausal women who have had menstrual bleeding&#xD;
             within 1 year) must be using a method of birth control considered to be appropriate by&#xD;
             the investigator (eg, abstinence, double barrier methods, hormonal contraceptives, or&#xD;
             partner with vasectomy) for the entire duration of the trial. Female subjects of&#xD;
             childbearing potential must agree to use appropriate birth control from the time of&#xD;
             Screening until at least 1 month after their last dose of study drug.&#xD;
&#xD;
             Women are considered to be not of childbearing potential if they are postmenopausal&#xD;
             (defined as amenorrheic for ≥12 months with a confirmed follicle stimulating hormone&#xD;
             [FSH] ≥ 40 mIU/mL) or if they have been surgically sterilized.&#xD;
&#xD;
          4. Male subjects must either: remain abstinent from intercourse, be sterile, or agree to&#xD;
             use a method of birth control considered to be appropriate by the investigator (eg,&#xD;
             condom with spermicide) from the time of Screening until 1 month after their last dose&#xD;
             of study drug.&#xD;
&#xD;
          5. Non smoker (and no use of other tobacco or nicotine containing products) as documented&#xD;
             by history (no nicotine use over the past 6 months) and a negative cotinine test at&#xD;
             Screening and Day 1.&#xD;
&#xD;
          6. Capable of understanding the written informed consent form (ICF) and providing signed&#xD;
             and witnessed written informed consent, as well as willing and able to comply with&#xD;
             protocol requirements.&#xD;
&#xD;
        Hemodialysis Subjects (Part 3)&#xD;
&#xD;
        Eligible subjects with ESRD requiring HD must meet all of the following criteria to qualify&#xD;
        for enrollment in this study:&#xD;
&#xD;
          1. Subject has end stage renal disease and is on a stable (defined as Kt/V ≥ 1.2 on two&#xD;
             occasions within 3 months of screening) HD regimen (prescribed at least 3 times/week)&#xD;
             for at least 3 months prior to screening.&#xD;
&#xD;
          2. 18 to 75 years of age (inclusive).&#xD;
&#xD;
          3. Serum calcium: 8.0 to 10.0 mg/dL; serum phosphorus: 3.0 to 7.0 mg/dL; and serum iPTH:&#xD;
             200 to 1000 pg/mL (at the time of Screening).&#xD;
&#xD;
          4. Subjects who have been receiving other vitamin D receptor analogs (eg, calcitriol,&#xD;
             paricalcitol [Zemplar], doxercalciferol [Hectorol]) must allow for a washout period of&#xD;
             3 weeks prior to study drug administration on Day 1.&#xD;
&#xD;
             Note: (1) If washout of VDRA therapy and/or cinacalcet is required, a check in visit&#xD;
             should be performed 1 week into the washout period to monitor for safety (at a&#xD;
             minimum, this visit will include laboratory testing for albumin corrected calcium;&#xD;
             additional assessments may be performed at the investigator's discretion). (2) The 3&#xD;
             week duration of washout may be adjusted on a case by case basis following discussion&#xD;
             and mutual agreement between the investigator and medical monitor.&#xD;
&#xD;
          5. A BMI between 18 and 40 kg/m2 (inclusive).&#xD;
&#xD;
          6. Female subjects of childbearing potential must be non pregnant and non lactating, and&#xD;
             have a negative serum pregnancy test at Screening and Day 1 (if initial serum hCG test&#xD;
             results are indeterminate, follow up testing should be performed). Female subjects of&#xD;
             childbearing potential (including perimenopausal women who have had menstrual bleeding&#xD;
             within 1 year) must be using a method of birth control considered to be appropriate by&#xD;
             the investigator (eg, abstinence, double barrier methods, hormonal contraceptives, or&#xD;
             partner with vasectomy) for the entire duration of the trial. Female subjects of&#xD;
             childbearing potential must agree to use appropriate birth control from the time of&#xD;
             Screening until 1 month after their last dose of study drug.&#xD;
&#xD;
             Women are considered to be not of childbearing potential if they are postmenopausal&#xD;
             (defined as amenorrheic for ≥12 months with a confirmed FSH ≥ 40 mIU/mL) or if they&#xD;
             have been surgically sterilized.&#xD;
&#xD;
          7. Male subjects must either: remain abstinent from intercourse, be sterile, or agree to&#xD;
             use a method of birth control considered to be appropriate by the investigator (eg,&#xD;
             condom with spermicide) from the time of Screening until 1 month after their last dose&#xD;
             of study drug.&#xD;
&#xD;
          8. Capable of understanding the written ICF and providing signed and witnessed written&#xD;
             informed consent, as well as willing and able to comply with protocol requirements.&#xD;
&#xD;
          9. Considered to be clinically stable with respect to underlying renal impairment, as&#xD;
             determined by investigator, and based upon a medical evaluation that includes a&#xD;
             medical history, physical examination, laboratory tests and ECG.&#xD;
&#xD;
         10. Subjects who need concurrent medications must have a medication regimen considered to&#xD;
             be stable by the investigator (eg, no new drugs or significant changes to dosage[s]&#xD;
             within 14 days prior to study drug administration on Day 1; no changes expected during&#xD;
             study conduct). Changes of medications in HD subjects are subject to dialysis site&#xD;
             protocols such that erythropoiesis stimulating agents (ESAs) and iron can be changed&#xD;
             based on the current subject status, the dialysis unit's standard of practice, and&#xD;
             subject safety. Changes to medications may be allowed at the discretion of the&#xD;
             investigator.&#xD;
&#xD;
         11. Subjects must have satisfactory control of blood pressure (as determined by the&#xD;
             investigator), and blood pressure at Screening must be ≤ 140/90 mmHg with confirmatory&#xD;
             repeat measurements allowed per the CRU's standard operating procedures (SOPs).&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
        Hemodialysis Subjects (Part 3)&#xD;
&#xD;
        Subjects undergoing hemodialysis who meet any of the following criteria will be excluded&#xD;
        from the study:&#xD;
&#xD;
          1. Receiving blood purification therapy other than hemodialysis.&#xD;
&#xD;
          2. Dialysis via central venous catheter.&#xD;
&#xD;
          3. Expected to undergo pre emptive or scheduled renal transplant within 6 months after&#xD;
             Screening.&#xD;
&#xD;
          4. Pregnant (positive pregnancy test) or lactating women, and male subjects whose female&#xD;
             partners are pregnant or lactating. If serum hCG pregnancy test results are&#xD;
             indeterminate, follow up testing should be performed to determine eligibility.&#xD;
&#xD;
          5. History of significant gastrointestinal, hepatic, broncho pulmonary, neurological,&#xD;
             psychiatric, cardiovascular, endocrinological, hematological or allergic disease,&#xD;
             metabolic disorder, cancer or cirrhosis, or any other unstable or new onset medical&#xD;
             conditions that, in the opinion of the investigator, would constitute a risk factor&#xD;
             for study participation or receipt of study drug.&#xD;
&#xD;
          6. ECG heart rate (HR) &lt;45 bpm or HR &gt;100 bpm; QTcF &gt;500 ms.&#xD;
&#xD;
          7. History of having received or currently receiving any systemic anti neoplastic&#xD;
             (including radiation) or immune modulatory treatment (including systemic oral&#xD;
             corticosteroids) ≤ 6 months prior to the first dose of study drug or such treatment is&#xD;
             expected to be needed at any time during the study.&#xD;
&#xD;
          8. Subjects who have had significant acute infection (eg, influenza, local infection,&#xD;
             acute gastrointestinal symptoms) or any other clinically significant illness within 2&#xD;
             weeks prior to the first dose of study drug.&#xD;
&#xD;
          9. History of significant gastrointestinal diseases (such as gastric or duodenal ulcers)&#xD;
             that affect the absorption of the study drug. Subjects with a history of&#xD;
             gastrointestinal disease may be allowed if there is no evidence of active disease for&#xD;
             3 months prior to Day 1 or at the discretion of the investigator.&#xD;
&#xD;
         10. Any confirmed significant allergic reactions (anaphylaxis or angioedema) against any&#xD;
             drug, or multiple drug allergies (non active hay fever is allowable per the&#xD;
             investigator's discretion).&#xD;
&#xD;
         11. Any clinically significant concomitant disease or condition (including treatment for&#xD;
             such conditions) that could either interfere with or, in the opinion of the&#xD;
             investigator, pose an unacceptable risk to the subject.&#xD;
&#xD;
         12. Positive test at Screening for Hepatitis B (HBsAg) or human immunodeficiency virus&#xD;
             (HIV Ab). If a subject has positive test results for Hepatitis C (HCV RNA or HCVAb)&#xD;
             but liver function tests are otherwise not clinically significant, the subject may be&#xD;
             included at the investigator's discretion.&#xD;
&#xD;
         13. Any other clinically significant abnormalities in laboratory test results at&#xD;
             Screening. In the case of uncertain or questionable results, tests performed during&#xD;
             Screening may be repeated before the first dose of study drug to confirm eligibility.&#xD;
&#xD;
         14. Treatment with another investigational drug or device study within 30 days or 5 half&#xD;
             lives (whichever is longer) prior to Screening.&#xD;
&#xD;
         15. Positive test for drugs of abuse and/or positive alcohol test at Screening or Day 1.&#xD;
&#xD;
         16. History of drug abuse or addiction within 6 months prior to Screening.&#xD;
&#xD;
         17. History (within 3 months of Screening) of alcohol consumption exceeding an average of&#xD;
             2 standard drinks per day (1 standard drink = 10 grams of alcohol). Alcohol&#xD;
             consumption will be prohibited, at a minimum, within 48 hours before Screening, and&#xD;
             from 48 hours before until 48 hours after each dose, and within 48 hours before each&#xD;
             scheduled visit.&#xD;
&#xD;
         18. Use of &gt; 5 cigarettes (or equivalent nicotine containing product) per day.&#xD;
&#xD;
         19. Use of the following:&#xD;
&#xD;
               1. any prescribed medications or herbal remedies within 3 weeks prior to first&#xD;
                  dosing, including any prescribed vitamin D analogs, cinacalcet, phosphate&#xD;
                  binders, and other agents that affect serum calcium and iPTH levels. Exceptions&#xD;
                  may be made at the discretion of the investigator including subjects on a stable&#xD;
                  dose of calcimimetics and/or phosphate binders for 3 months prior to first&#xD;
                  dosing;&#xD;
&#xD;
               2. use of any OTC medications (including vitamins and supplements) within 2 weeks&#xD;
                  prior to first dosing, unless specifically indicated for an underlying&#xD;
                  concomitant condition.&#xD;
&#xD;
             Note: exceptions may be made to this criterion (#19) on a case by case basis following&#xD;
             discussion and agreement between the investigator and the medical monitor.&#xD;
&#xD;
         20. Planned parathyroid intervention during the study period.&#xD;
&#xD;
         21. Use of medications or nutrients known to modulate CYP3A and/or 5' diphospho&#xD;
             glucoronosyltransferase (UGT) activity, based on the VS 105 metabolic pathway:&#xD;
&#xD;
               1. strong or moderate inhibitors of CYP3A4 and/or UGT within 2 weeks prior to first&#xD;
                  dose administration, including but not limited to the following drugs:&#xD;
                  ketoconazole, miconazole, itraconazole, fluconazole, atazanavir, erythromycin,&#xD;
                  clarithromycin, ranitidine, cimetidine, verapamil, and diltiazem;&#xD;
&#xD;
               2. any strong or moderate inducer of CYP3A4 and/or UGT, within 4 weeks prior to&#xD;
                  first dose administration, including but not limited to the following drugs:&#xD;
                  rifampicin, rifabutin, glucocorticoids, carbamazepine, phenytoin, phenobarbital,&#xD;
                  and St. John's wort.&#xD;
&#xD;
             Note: at the discretion of the investigator, the study pharmacist and/or medical&#xD;
             monitor may review the subject's medication list to assist with eligibility&#xD;
             determination in regard to this criterion (#21).&#xD;
&#xD;
         22. Subjects under judicial supervision, guardianship or curatorship, or with other&#xD;
             medical or social conditions that would potentially interfere with the subject's&#xD;
             ability to comply with the study visit schedule or the study assessments.&#xD;
&#xD;
         23. Blood donation or significant blood loss (ie, &gt; 500 mL) within 56 days prior to Day 1.&#xD;
&#xD;
         24. Plasma or platelet donation within 14 days prior to Day 1.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adam Hardies</last_name>
    <role>Study Director</role>
    <affiliation>Davita Clinical Research</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Robert Williams</last_name>
    <role>Principal Investigator</role>
    <affiliation>Davita Clinical Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>DaVita Clinical Research</name>
      <address>
        <city>Lakewood</city>
        <state>Colorado</state>
        <zip>80228</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>January 27, 2017</study_first_submitted>
  <study_first_submitted_qc>February 3, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 6, 2017</study_first_posted>
  <last_update_submitted>October 2, 2019</last_update_submitted>
  <last_update_submitted_qc>October 2, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 7, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>VS-105</keyword>
  <keyword>Renal Insufficiency, Chronic</keyword>
  <keyword>Secondary hyperparathyroidism</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calcitriol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT03043482
org study id: VS 105 SAD MAD 001
nct id: NCT03043482
lead sponsor: 
has dmc: No
is fda regulated drug: Yes
is fda regulated device: No
The purpose of the study is to evaluate the safety, tolerability, and PK following single and
      multiple ascending dose administration of VS-105 in healthy subjects and patients with
      chronic kidney disease stage 5D (CKD-5D) on hemodialysis.
This is a first in human, 3 part, single and multiple ascending dose study in healthy
      subjects and subjects with end stage renal disease (ESRD) requiring hemodialysis (HD). A
      Safety Monitoring Committee (SMC) will evaluate safety data from each dose cohort before
      proceeding with the subsequent cohort. The SMC will also review data from each Part of the
      study before proceeding to the next scheduled Part.

      In Part 1, single ascending doses (SAD) of VS 105 will be administered to approximately 5
      dose cohorts of 8 healthy subjects each. In Part 2, multiple ascending doses (MAD) of VS 105
      will be administered to approximately 3 dose cohorts of 8 healthy subjects each. VS 105 doses
      for MAD cohorts in Part 2 will be determined by the SMC and based on results from Part 1.

      In Part 3, MAD of VS 105 will be administered to approximately 3 successive dose cohorts that
      will each include 4 subjects with ESRD requiring HD. VS 105 doses used in Part 3 will be
      selected by the SMC based on review of safety and/or pharmacokinetic (PK) results from Part 1
      and Part 2.

      Parts 1 & 2 of the study will assess the safety, tolerability, and PK of ascending doses of
      VS 105 to determine the dose range that is safe and well tolerated in healthy subjects.

      Part 3 of the study will assess the safety, tolerability, and PK of various doses of VS 105
      in subjects with ESRD requiring HD (ie, HD subjects), who represent the target population
      with secondary hyperparathyroidism (SHPT).
allocation: Randomized
intervention model: Parallel Assignment
primary purpose: Treatment
masking: Double (Participant, Investigator)
measure: Safety and tolerability of single and multiple ascending doses of VS 105 administered orally to healthy and HD subjects (numbers and percentages of adverse events).
time frame: 3 weeks
description: Adverse events will be counted within each treatment and study part. The numbers and percentages of adverse events will be tabulated by body system, preferred term, and severity.
measure: Pharmacokinetic (PK) of VS-105 in serum: area under the serum concentration-time curve from time zero to the time of the last quantifiable concentration
time frame: pre-dose and 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12 and 16 hours and 2, 3, 7, 8, 9, 14, 15, 16 days after dosing.
description: AUC0-last: The area under the serum concentration-time curve from time zero to the time of the last quantifiable concentration.
measure: PK of VS-105 in serum: area under the serum concentration-time curve from time zero to infinity.
time frame: pre-dose and 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12 and 16 hours and 2, 3, 7, 8, 9, 14, 15, 16 days after dosing.
description: AUC0-∞: The area under the serum concentration-time curve from time zero to infinity
measure: PK of VS-105 in serum: observed maximum serum concentration following drug administration
time frame: pre-dose and 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12 and 16 hours and 2, 3, 7, 8, 9, 14, 15, 16 days after dosing.
description: Cmax: The observed maximum serum concentration following drug administration
measure: PK of VS-105 in serum: terminal elimination half-life
time frame: pre-dose and 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12 and 16 hours and 2, 3, 7, 8, 9, 14, 15, 16 days after dosing.
description: T1/2: The terminal elimination half-life
measure: PK of VS-105 in serum: time to reach the maximum concentration after drug administration
time frame: pre-dose and 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12 and 16 hours and 2, 3, 7, 8, 9, 14, 15, 16 days after dosing.
description: Tmax: The time to reach the maximum concentration after drug administration
measure: Serum calcium (ionized) in healthy and HD subjects
time frame: Pre-dose and 1, 2, 15, 21 days after dosing
description: To evaluate the changes from baseline in concentrations of serum calcium (ionized) in healthy and HD subjects after multiple doses of VS 105 (Part 2 and Part 3 only).
measure: Serum phosphorous in healthy and HD subjects
time frame: Pre-dose and 1, 2, 15, 21 days after dosing
description: To evaluate the changes from baseline in concentrations of serum phosphorous in healthy and HD subjects after multiple doses of VS 105 (Part 2 and Part 3 only).
measure: Serum intact parathyroid hormone (iPTH) in healthy and HD subjects
time frame: Pre-dose and 1, 2, 15, 21 days after dosing
description: To evaluate the changes from baseline in concentrations of serum intact parathyroid hormone (iPTH) in healthy and HD subjects after multiple doses of VS 105 (Part 2 and Part 3 only).
arm group label: Single VS-105/placebo to healthy
arm group type: Experimental
description: Single ascending dose VS-105 or placebo to healthy subjects
arm group label: Multiple VS-105/placebo to healthy
arm group type: Experimental
description: Multiple ascending dose VS-105 or placebo to healthy subjects
arm group label: Multiple VS-105/placebo to HD subjects
arm group type: Experimental
description: Multiple ascending dose VS-105 or placebo to hemodialysis (HD) subjects
intervention type: Drug
intervention name: Single VS-105/placebo to healthy
description: In Part 1, single ascending doses of VS-105 or placebo will be administered to approximately 5 cohorts of 8 healthy subjects in each cohort with 6 receiving active and 2 receiving placebo.
arm group label: Single VS-105/placebo to healthy
other name: CK15
intervention type: Drug
intervention name: Multiple VS-105/placebo to healthy
description: In Part 2, multiple ascending doses of VS 105 or placebo will be administered each morning over 7 consecutive days to approximately 3 cohorts of 8 healthy subjects in each cohort with 6 receiving active and 2 receiving placebo..
arm group label: Multiple VS-105/placebo to healthy
other name: CK15
intervention type: Drug
intervention name: Multiple VS-105/placebo to HD subjects
description: In Part 3, multiple ascending doses of VS 105 will be administered over 14 consecutive days to approximately 3 cohorts that will each include 4 hemodialysis subjects with 3 receiving active drug and 1 receiving placebo.
arm group label: Multiple VS-105/placebo to HD subjects
other name: CK15
criteria: 
gender: All
minimum age: 18 Years
maximum age: 75 Years
healthy volunteers: Accepts Healthy Volunteers
last name: Adam Hardies
role: Study Director
affiliation: Davita Clinical Research
last name: Robert Williams
role: Principal Investigator
affiliation: Davita Clinical Research
facility: 
country: United States
responsible party type: Sponsor
mesh term: Kidney Diseases
mesh term: Renal Insufficiency, Chronic
mesh term: Calcitriol
sharing ipd: No